PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. Its lead product candidates comprise PGN-EDO51, an EDO peptide which is Phase 2 clinical trial to treat duchenne muscular dystrophy (DMD) patients that are amenable to an exon 51-skipping approach; PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and PGN-EDO53, which is in preclinical trial to treat duchenne muscular dystrophy. The company was founded in 2018 and is based in Boston, Massachusetts.

PepGen Inc.

In a report released today, Paul Matteis from Stifel Nicolaus maintained a Buy rating on PepGen Inc., with a price target of $12.00. Matteis covers...

Stifel Nicolaus Remains a Buy on PepGen Inc. (PEPG)

Bank of America Securities analyst Tazeen Ahmad reiterated a Sell rating on PepGen Inc. today and set a price target of $2.50. According to TipRank...

Bank of America Securities Sticks to Its Sell Rating for PepGen Inc. (PEPG)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on GoodRx Holdings (GDRX), Xencor (XNCR) and PepGen I...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	PEPG	$3.04	+1.67%	670.59K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	PEPG	$3.04	+1.7%	670.59K
3
4
5
6

PEPG

Get PepGen Inc. Data in Excel

Get PepGen Inc. Data in Excel